

NeoVista Inc. Announces the Appointment of Jeffrey Nau to Position of Vice President of Medical and Clinical Affairs

Management Team at NeoVista is Further Strengthened

Fremont, CA ([PRWEB](#)) November 12, 2009 -- NeoVista, Inc., an ophthalmic medical device company today announced the promotion of Jeffrey Nau to Vice President of Medical and Clinical Affairs. Mr. Nau previously served as Executive Director of Medical and Clinical Affairs for the company.

"I am pleased to continue working with such a great team at NeoVista to develop this revolutionary device for patients with Age-Related Macular Degeneration", stated Mr. Nau. Prior to joining NeoVista, Inc. in 2006, Mr. Nau served in various capacities for Acuity Pharmaceuticals and Genaera Corporation. He received a Medical Science degree from MCP Hahnemann University School of Medicine in 2002 and a BS in Biology from Stony Brook University in 1997. He is a former Research Fellow of the Wills Eye Hospital Ocular Oncology Service.

"It has been rewarding to observe the continued growth of Jeff within the organization", stated John N. Hendrick, President and CEO of NeoVista, Inc. "Through Jeff's guidance, we were able to recently complete patient enrollment in our company's initial Pivotal Trial, the CABERNET Study, comparing our technology to today's standard of care. It is our hope that upon one-year follow-up, the trial data will support FDA approval in a most timely manner so that retinal surgeons, patients, and health care systems in the US and around the world will have a cost effective option available for treating this dreadful disease."

About NeoVista, Inc.

NeoVista, Inc. is a privately held medical device company based in Fremont, California. The company's first commercial product, the VIDION® ANV® Therapy System, is now being commercialized in various countries that accept a CE Mark.

NeoVista, Inc is hoping to begin commercial activity in the US in early 2011. For more information about the company, or the company's novel neovascular AMD therapy, please visit the company's Web site at www.neovistainc.com.